Search

Your search keyword '"Grivas, P."' showing total 303 results

Search Constraints

Start Over You searched for: Author "Grivas, P." Remove constraint Author: "Grivas, P." Search Limiters Peer Reviewed Remove constraint Search Limiters: Peer Reviewed
303 results on '"Grivas, P."'

Search Results

1. Single-Hit and Multi-hit PIK3CA Short Variant Genomic Alterations in Clinically Advanced Prostate Cancer: A Genomic Landscape Study

4. Long-term survival following anti-PD-(L)1 monotherapy in advanced urothelial cancer and an assessment of potential prognostic clinical factors: a multicentre observational study

8. Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial

10. TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes

14. Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer

18. Multicenter evaluation of neoadjuvant and induction gemcitabine–carboplatin versus gemcitabine–cisplatin followed by radical cystectomy for muscle-invasive bladder cancer

20. Frequency and impact of a genome-wide homologous recombination deficiency signature (HRDsig+) on the genomic landscape of clinically advanced penile squamous cell carcinoma (CAPSCC).

22. Outcomes of enfortumab vedotin and pembrolizumab for patients previously treated with immune checkpoint inhibitors in the UNITE study.

23. Frequency and impact of a genome-wide homologous recombination deficiency signature (HRDsig+) on the genomic landscape of clinically advanced urothelial bladder carcinoma (CAUBC).

27. MTAP loss in primary kidney tumors: A comprehensive genomic profiling study.

31. COVID-19 vaccination and breakthrough infections in patients with cancer

33. Nomogram Predicting Bladder Cancer–specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium

37. Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer

38. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

39. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma

40. TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy.

42. An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer

46. Establishing consensus on the best practice guidelines for the use of bracing in adolescent idiopathic scoliosis

47. Blood Myeloid-Derived Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in Metastatic Urothelial Carcinoma

48. Transition technologies towards 6G networks

49. Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)

Catalog

Books, media, physical & digital resources